ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-1/Anti-VEGFR2 Bispecific Antibody OTP-01

Its studies are led by Ottimo Pharma.

Furthest: phase 2, since Nov 16, 20251 company-led study, 1 open or runningNext primary completion: Dec 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ottimo Pharma11 open or runningphase 2since Nov 16, 2025Nov 16, 2025Dec 2028phase 2 · NCT07266428

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 16, 2025First study: phase 2 study in Advanced Solid TumorsFirst studyNCT07266428 · 170 planned · United States, Australia, Brazil and more

Ahead

  1. Dec 2028Primary completion: phase 2 study in Advanced Solid TumorsNCT07266428

TargetBeta

KDR →PDCD1 →read by rule
“An immunoglobulin G1 (IgG1) Fc-null bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor receptor 2 (VEGFR2; VEGFR-2), ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07266428Advanced Solid Tumors · United States, Australia, Brazil and more2RecruitingDec 2028170

How it is read

Names in the registry

  • “OTP-01”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.